DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
141.50
-4.78 (-3.27%)
Apr 16, 2025, 4:00 PM EDT - Market closed
DaVita Revenue
In the year 2024, DaVita had annual revenue of $12.82B with 5.56% growth. DaVita had revenue of $3.29B in the quarter ending December 31, 2024, with 4.73% growth.
Revenue (ttm)
$12.82B
Revenue Growth
+5.56%
P/S Ratio
0.94
Revenue / Employee
$168,626
Employees
76,000
Market Cap
11.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12.82B | 675.40M | 5.56% |
| Dec 31, 2023 | 12.14B | 530.25M | 4.57% |
| Dec 31, 2022 | 11.61B | -8.90M | -0.08% |
| Dec 31, 2021 | 11.62B | 68.19M | 0.59% |
| Dec 31, 2020 | 11.55B | 162.13M | 1.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
DVA News
- 2 days ago - DaVita Says Ransomware Attack Affecting Some Operations - WSJ
- 2 days ago - Dialysis firm DaVita hit by ransomware attack - Reuters
- 16 days ago - These 15 stocks are the most profitable companies in the S&P 500 - Market Watch
- 5 weeks ago - DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2025 - PRNewsWire
- 6 weeks ago - YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities - GlobeNewsWire
- 2 months ago - Berkshire Hathaway sells another 750,000 DaVita shares - Reuters
- 2 months ago - DaVita's stock leads S&P 500 decliners after Berkshire pares stake. Its soft guidance isn't helping. - Market Watch
- 2 months ago - Warren Buffett's Berkshire Hathaway sells some DaVita; Shares fall on disappointing guidance - CNBC